The Future of the COVID-19 Response: The New Administration, Vaccines, and the Health Care System

SPEAKER BIOGRAPHIES
(In order of appearance on the program)

**KATHRYN SANTORO, MA** is Director of Programming at the National Institute for Health Care Management (NIHCM) Foundation, a nonprofit and nonpartisan organization dedicated to transforming health care through evidence and collaboration. Ms. Santoro currently leads NIHCM’s programs to highlight market and policy innovations, including webinars and Capitol Hill briefings, and directs the organization’s journalism and population health programs.

Ms. Santoro joined NIHCM Foundation in September 2004 after receiving her Master’s degree in Public Policy from George Washington University with a focus on women’s health policy. Ms. Santoro previously served as a Project Consultant for Women in Government where she was responsible for compiling a state-by-state report card on access to cervical cancer screening. While pursuing her Master’s degree, Ms. Santoro was a Communications Assistant for a health policy consulting firm and a Graduate Intern for a Washington, D.C. based women’s and children’s policy research organization. Ms. Santoro attended Villanova University in Villanova, PA and graduated with a BA cum laude in Political Science.

**MICHAEL T. OSTERHOLM, PhD, MPH** is Regents Professor, McKnight Presidential Endowed Chair in Public Health, the director of the Center for Infectious Disease Research and Policy (CIDRAP), Distinguished Teaching Professor in the Division of Environmental Health Sciences, School of Public Health, a professor in the Technological Leadership Institute, College of Science and Engineering, and an adjunct professor in the Medical School, all at the University of Minnesota. From June 2018 through May 2019, he served as a Science Envoy for Health Security on behalf of the US Department of State. He is also on the Board of Regents at Luther College in Decorah, Iowa.

He is the author of the *New York Times* best-selling 2017 book, *Deadliest Enemy: Our War Against Killer Germs*, in which he not only details the most pressing infectious disease threats of our day but lays out a nine-point strategy on how to address them, with preventing a global flu pandemic at the top of the list.
In addition, Dr. Osterholm is a member of the National Academy of Medicine (NAM) and the Council of Foreign Relations. In June 2005 Dr. Osterholm was appointed by Michael Leavitt, Secretary of the Department of Health and Human Services (HHS), to the newly established National Science Advisory Board on Biosecurity. In July 2008, he was named to the University of Minnesota Academic Health Center’s Academy of Excellence in Health Research. In October 2008, he was appointed to the World Economic Forum Working Group on Pandemics. From 2001 through early 2005, Dr. Osterholm, in addition to his role at CIDRAP, served as a Special Advisor to then–HHS Secretary Tommy G. Thompson on issues related to bioterrorism and public health preparedness. He was also appointed to the Secretary's Advisory Council on Public Health Preparedness. On April 1, 2002, Dr. Osterholm was appointed by Thompson to be his representative on the interim management team to lead the Centers for Disease Control and Prevention (CDC). With the appointment of Dr. Julie Gerberding as director of the CDC on July 3, 2002, Dr. Osterholm was asked by Thompson to assist Dr. Gerberding on his behalf during the transition period. He filled that role through January 2003.

Previously, Dr. Osterholm served for 24 years (1975-1999) in various roles at the Minnesota Department of Health, the last 15 as state epidemiologist. He has led numerous investigations of outbreaks of international importance, including foodborne diseases, the association of tampons and toxic shock syndrome, and hepatitis B and HIV in healthcare settings. Dr. Osterholm was the principal investigator and director of the NIH-supported Minnesota Center of Excellence for Influenza Research and Surveillance (2007-2014) and chaired the Executive Committee of the Centers of Excellence Influenza Research and Surveillance network. Dr. Osterholm has been an international leader on the critical concern regarding our preparedness for an influenza pandemic. His invited papers in the journals Foreign Affairs, the New England Journal of Medicine, and Nature detail the threat of an influenza pandemic before the recent pandemic and the steps we must take to better prepare for such events. Dr. Osterholm has also been an international leader on the growing concern regarding the use of biological agents as catastrophic weapons targeting civilian populations. In that role, he served as a personal advisor to the late King Hussein of Jordan. Dr. Osterholm provides a comprehensive and pointed review of America's current state of preparedness for a bioterrorism attack in his New York Times best-selling book, Living Terrors: What America Needs to Know to Survive the Coming Bioterrorist Catastrophe.

The author of more than 315 papers and abstracts, including 21 book chapters, Dr. Osterholm is a frequently invited guest lecturer on the topic of epidemiology of infectious diseases. He serves on the editorial boards of nine journals, including Infection Control and Hospital Epidemiology and Microbial Drug Resistance: Mechanisms, Epidemiology and Disease, and he is a reviewer for 24 additional journals, including the New England Journal of Medicine, the Journal of the American Medical Association, and Science. He is past president of the Council of State and Territorial Epidemiologists (CSTE) and has served on the CDC’s National Center for Infectious Diseases Board of Scientific Counselors from 1992 to 1997. Dr. Osterholm served on the IOM Forum on Microbial Threats from 1994 through 2011. He has served on the IOM Committee on Emerging Microbial Threats to Health in the 21st Century and the IOM
Committee on Food Safety, Production to Consumption, and he was a reviewer for the IOM Report on Chemical and Biological Terrorism. As a member of the American Society for Microbiology (ASM), Dr. Osterholm has served on the Committee on Biomedical Research of the Public and Scientific Affairs Board, the Task Force on Biological Weapons, and the Task Force on Antibiotic Resistance. He is a frequent consultant to the World Health Organization (WHO), the National Institutes of Health (NIH), the Food and Drug Administration (FDA), the Department of Defense, and the CDC. He is a fellow of the American College of Epidemiology and the Infectious Diseases Society of America (IDSA).

Dr. Osterholm has received numerous honors for his work, including an honorary doctorate from Luther College; the Pump Handle Award, CSTE; the Charles C. Shepard Science Award, CDC; the Harvey W. Wiley Medal, FDA; the Squibb Award, IDSA; Distinguished University Teaching Professor, Environmental Health Sciences, School of Public Health, UMN; and the Wade Hampton Frost Leadership Award, American Public Health Association. He also has been the recipient of six major research awards from the NIH and the CDC.

Hemi Tewarson, JD, MPH is a Senior Policy Fellow at the Duke-Margolis Center for Health Policy. Hemi has senior strategic responsibilities in the Center’s continued development and expansion of a substantial state health policy research and analysis program at Duke-Margolis. Specifically, Hemi will help strengthen the Center’s engagement in state-level COVID-19 response, including such areas as new models of care and effective strategies for COVID-19 testing and containment. Previously, Hemi served as the director for the Health Division of the National Governors Association’s (NGA) Center for Best Practices, overseeing a broad project portfolio including Medicaid transformation and coverage, Medicaid data systems, health care delivery and payment system reform, workforce, opioids, and behavioral health and social determinants. Prior to joining NGA, Hemi served as senior attorney for the Office of the General Counsel at the U.S. Government Accountability Office.

Katherine Dallow, MD, MPH is Vice President and Medical Director, Clinical Programs and Strategy for Blue Cross Blue Shield of Massachusetts.

Throughout her career, Dr. Dallow has held executive leadership positions within both health plans and accountable care organizations. Prior roles have included Vice President of Clinical Affairs and Quality for Blue Cross & Blue Shield of Rhode Island (BCBSRI) and Medical Director for Managed Care for the Beth Israel Deaconess Care Organization (BIDCO). She is an experienced physician executive and leader with a proven track record in value based contract management, quality metrics analysis and performance, practice pattern variation analysis, medical and pharmacy trend management, high risk care management and care coordination, and risk adjustment.

She is a board certified internal medicine physician who practiced for 15 years in the Beth Israel Deaconess system in Boston and several of its surrounding suburban communities. She earned a Masters in Public Health in health care policy and management from the Harvard School of
Public Health, a medical degree from Jefferson Medical College of Thomas Jefferson University in Philadelphia, and a Bachelor’s of Arts in English and American Studies from Princeton University. Dr. Dallow also holds the Certified Physician Executive designation through the American Association of Physician Leadership.

Dr. Dallow serves as Chair of the New England Chapter of the American Diabetes Association Community Leadership Board and serves on the board of the New England Chapter of Playworks.